Icsm Avoid Tt For Fracture Risk Reduction

Avoid testosterone therapy alone for reducing fracture risk in high-risk hypogonadal men

STEP 1 — Gather Information

Confirm hypogonadism: low total testosterone (<12 nmol/L or <350 ng/dL) on two morning fasting samples plus symptoms (low libido, fatigue, ED). Assess fracture risk: FRAX score, prior fragility fracture, BMD T‑score ≤‑2.5, or clinical risk factors (age, glucocorticoids, falls). Record calcium/vitamin D status and lifestyle factors.

STEP 2 — Rule In / Rule Out

Is the patient at high fracture risk (e.g., FRAX major osteoporotic fracture probability >20% or hip fracture >3%, prior fragility fracture, or T‑score ≤‑2.5)?

• If NO, testosterone therapy may be considered for other indications (e.g., symptomatic hypogonadism) but not for fracture prevention.
• If YES, proceed to Step 3.

STEP 3 — Classify or Stratify

Classify as high‑risk hypogonadal man requiring osteoporosis‑directed therapy, not testosterone monotherapy for bone health. Note that testosterone may increase BMD but is not recommended as sole fracture‑risk reduction strategy.

STEP 4 — Decide

Do not prescribe testosterone therapy alone to reduce fracture risk. Initiate guideline‑based osteoporosis treatment (e.g., oral bisphosphonate, denosumab, or teriparatide based on risk) and ensure calcium/vitamin D repletion. Consider testosterone therapy only if symptomatic hypogonadism persists after bone‑health optimization.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on testosterone to prevent fractures as primary therapy; avoid using testosterone in eugonadal men; do not substitute testosterone for approved osteoporosis agents; monitor for polycythemia, edema, and worsening sleep apnea when testosterone is used for other indications.

Concrete Clinical Example

A 68‑year‑old man with total testosterone 8 nmol/L, fatigue, low libido, and a recent vertebral fracture (T‑score ‑2.8) asks if testosterone will strengthen his bones. Clinician declines testosterone monotherapy, starts weekly alendronate plus calcium/vitamin D, and evaluates testosterone therapy for persistent symptoms after 3 months.

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036